EBS RSI Chart
Last 7 days
27.6%
Last 30 days
192.1%
Last 90 days
255.8%
Trailing 12 Months
-35.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 1.2B | 0 | 0 | 0 |
2023 | 977.0M | 1.1B | 1.1B | 1.0B |
2022 | 1.7B | 1.6B | 1.5B | 1.1B |
2021 | 1.7B | 1.7B | 1.6B | 1.8B |
2020 | 1.1B | 1.3B | 1.3B | 1.6B |
2019 | 855.2M | 878.2M | 1.0B | 1.1B |
2018 | 561.8M | 681.2M | 705.5M | 782.4M |
2017 | 502.7M | 512.3M | 518.8M | 560.9M |
2016 | 540.1M | 512.4M | 496.9M | 488.8M |
2015 | 448.4M | 457.1M | 477.5M | 489.3M |
2014 | 323.5M | 351.4M | 400.3M | 450.1M |
2013 | 274.7M | 286.7M | 309.2M | 312.7M |
2012 | 305.2M | 287.4M | 295.2M | 281.9M |
2011 | 257.9M | 283.9M | 268.7M | 273.4M |
2010 | 0 | 251.9M | 269.0M | 286.2M |
2009 | 0 | 0 | 0 | 234.8M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 07, 2024 | hartzel william | sold (taxes) | -1,522 | 2.29 | -665 | svp, bioservices |
Apr 07, 2024 | glessner coleen | sold (taxes) | -1,339 | 2.29 | -585 | evp, quality & ethics, and cpl |
Mar 05, 2024 | hartzel william | sold (taxes) | -1,179 | 3.41 | -346 | svp, bioservices |
Mar 01, 2024 | williams paul anthony | sold (taxes) | -464 | 3.39 | -137 | svp, products business |
Mar 01, 2024 | glessner coleen | sold (taxes) | -1,291 | 3.39 | -381 | evp, quality & ethics, and cpl |
Mar 01, 2024 | lindahl richard s | sold (taxes) | -2,318 | 3.39 | -684 | evp, chief financial officer |
Mar 01, 2024 | fox jennifer lynne | sold (taxes) | -2,383 | 3.39 | -703 | evp, ext aff, gc, corp sec |
Feb 29, 2024 | lindahl richard s | sold (taxes) | -29,189 | 3.23 | -9,037 | evp, chief financial officer |
Feb 29, 2024 | williams paul anthony | sold (taxes) | -1,453 | 3.23 | -450 | svp, products business |
Feb 29, 2024 | fox jennifer lynne | sold (taxes) | -13,252 | 3.23 | -4,103 | evp, ext aff, gc, corp sec |
Which funds bought or sold EBS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.93 | -7,317 | 13,227 | -% |
May 16, 2024 | Tidal Investments LLC | new | - | 33,781 | 33,781 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -50.13 | -281,206 | 311,635 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | reduced | -61.04 | -1,063,360 | 741,171 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -57.33 | -2,767,370 | 2,262,220 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -2.41 | 71,692 | 2,564,330 | 0.01% |
May 15, 2024 | MORGAN STANLEY | added | 4.72 | 308,211 | 3,273,070 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -6.02 | -9,498 | 1,007,100 | -% |
May 15, 2024 | AQR CAPITAL MANAGEMENT LLC | added | 104 | 1,370,750 | 2,602,950 | -% |
May 15, 2024 | BARCLAYS PLC | reduced | -72.63 | -239,000 | 97,000 | -% |
Unveiling Emergent BioSolutions Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Emergent BioSolutions Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Emergent BioSolutions Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 8.6% | 300 | 277 | 271 | 338 | 164 | 330 | 240 | 243 | 305 | 733 | 286 | 377 | 377 | 583 | 385 | 395 | 193 | 360 | 312 | 243 | 191 |
Operating Expenses | -18.5% | 261 | 320 | 513 | 631 | 313 | 386 | 285 | 315 | 301 | 438 | 364 | 383 | 248 | 342 | 324 | 269 | 204 | 283 | 241 | 250 | 218 |
S&GA Expenses | -6.0% | 85.00 | 90.00 | 86.00 | 91.00 | 101 | 93.00 | 82.00 | 81.00 | 85.00 | 95.00 | 82.00 | 91.00 | 81.00 | 83.00 | 76.00 | 76.00 | 70.00 | 72.00 | 65.00 | 71.00 | 65.00 |
R&D Expenses | -48.7% | 15.00 | 29.00 | 15.00 | 26.00 | 41.00 | 48.00 | 42.00 | 50.00 | 46.00 | 38.00 | 50.00 | 49.00 | 53.00 | 63.00 | 84.00 | 48.00 | 43.00 | 63.00 | 53.00 | 64.00 | 46.00 |
EBITDA Margin | 41.0% | -0.29* | -0.49* | -0.48* | -0.32* | -0.18* | -0.03* | 0.18* | 0.19* | 0.22* | 0.26* | 0.28* | 0.32* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 12.0% | 24.00 | 22.00 | 20.00 | 29.00 | 18.00 | 13.00 | 9.00 | 8.00 | 8.00 | 9.00 | 8.00 | 9.00 | 9.00 | 9.00 | 8.00 | 6.00 | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 |
Income Taxes | 200.0% | 3.00 | -3.10 | -2.50 | 11.00 | 22.00 | 2.00 | 20.00 | -26.40 | -0.10 | 78.00 | -12.80 | 3.00 | 16.00 | 71.00 | 16.00 | 28.00 | -8.80 | 25.00 | 16.00 | -5.60 | -11.80 |
Earnings Before Taxes | 122.3% | 12.00 | -54.25 | -265 | -250 | -161 | -63.30 | -67.20 | -82.80 | -3.80 | 256 | -45.50 | 7.00 | 85.00 | 258 | 55.00 | 121 | -21.30 | 71.00 | 59.00 | -15.10 | -37.80 |
EBT Margin | 32.4% | -0.47* | -0.70* | -0.67* | -0.51* | -0.38* | -0.19* | 0.07* | 0.08* | 0.13* | 0.17* | 0.19* | 0.24* | - | - | - | - | - | - | - | - | - |
Net Income | 118.2% | 9.00 | -49.50 | -263 | -261 | -186 | -67.00 | -87.10 | -52.90 | -4.60 | 193 | -40.40 | -0.50 | 67.00 | 185 | 40.00 | 93.00 | -12.50 | 47.00 | 43.00 | -9.50 | -26.10 |
Net Income Margin | 34.2% | -0.48* | -0.72* | -0.71* | -0.56* | -0.40* | -0.19* | 0.03* | 0.06* | 0.09* | 0.12* | 0.13* | 0.17* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -454.6% | -73.40 | 21.00 | 47.00 | -126 | -199 | 69.00 | -101 | -47.70 | -69.50 | 282 | -38.50 | -96.70 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.1% | 1,804 | 1,823 | 1,893 | 2,179 | 2,950 | 3,166 | 2,896 | 2,735 | 2,780 | 2,958 | 2,868 | 2,915 | 2,900 | 2,883 | 2,616 | 2,466 | 2,279 | 2,327 | 2,334 | 2,321 | 2,154 |
Current Assets | 0.4% | 682 | 680 | 721 | 778 | 1,221 | 1,210 | 1,098 | 1,084 | 1,100 | 1,270 | 1,112 | 1,162 | 1,181 | 1,196 | 959 | 796 | 627 | 686 | 700 | 693 | 529 |
Cash Equivalents | -29.3% | 79.00 | 112 | 88.00 | 89.00 | 430 | 643 | 241 | 358 | 436 | 576 | 404 | 448 | 548 | 622 | 415 | 269 | 182 | 168 | 139 | 178 | 137 |
Inventory | 1.4% | 333 | 329 | 354 | 354 | 368 | 351 | 528 | 426 | 401 | 345 | 365 | 386 | 407 | 307 | 270 | 236 | 248 | 223 | 230 | 232 | 211 |
Net PPE | -0.9% | 379 | 383 | 395 | 396 | 717 | 818 | 807 | 798 | 808 | 800 | 769 | 744 | 693 | 644 | 607 | 580 | 549 | 542 | 529 | 521 | 513 |
Goodwill | - | - | - | - | 218 | 218 | 218 | 225 | 225 | 225 | 225 | 267 | 267 | 267 | 267 | 267 | 266 | 266 | 267 | 269 | 268 | 268 |
Liabilities | -2.9% | 1,140 | 1,174 | 1,196 | 1,223 | 1,747 | 1,779 | 1,463 | 1,222 | 1,205 | 1,346 | 1,345 | 1,372 | 1,377 | 1,436 | 1,365 | 1,267 | 1,204 | 1,239 | 1,299 | 1,332 | 1,166 |
Current Liabilities | -3.2% | 630 | 651 | 664 | 693 | 1,216 | 1,229 | 264 | 277 | 249 | 374 | 365 | 378 | 370 | 385 | 299 | 294 | 207 | 216 | 275 | 301 | 248 |
Long Term Debt | 0.0% | 447 | 447 | 448 | 448 | 448 | 449 | 1,032 | 794 | 802 | 809 | 817 | 825 | 833 | 841 | 849 | 758 | 763 | 798 | 813 | 830 | 732 |
LT Debt, Current | 11.0% | 459 | 414 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.00 | 10.00 | 10.00 |
LT Debt, Non Current | -100.0% | - | 447 | 448 | 448 | 448 | 449 | 1,032 | 794 | 802 | 809 | 817 | 825 | 833 | 841 | 849 | 758 | 763 | 798 | 813 | 830 | 732 |
Shareholder's Equity | 2.2% | 664 | 649 | 697 | 958 | 1,204 | 1,388 | 1,433 | 1,508 | 1,567 | 1,612 | 1,523 | 1,544 | 1,523 | 1,451 | 1,252 | 1,199 | 1,075 | 1,091 | 1,035 | 989 | 987 |
Retained Earnings | 41.3% | -12.80 | -21.80 | 28.00 | 290 | 551 | 739 | 806 | 898 | 954 | 950 | 769 | 801 | 797 | 727 | 542 | 502 | 409 | 422 | 375 | 332 | 341 |
Additional Paid-In Capital | 0.6% | 910 | 904 | 900 | 896 | 878 | 874 | 860 | 849 | 835 | 829 | 817 | 804 | 790 | 785 | 771 | 759 | 726 | 716 | 709 | 702 | 690 |
Shares Outstanding | 0.4% | 52.00 | 52.00 | 52.00 | 52.00 | 50.00 | 50.00 | 50.00 | 50.00 | 51.00 | 54.00 | 54.00 | 54.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 381 | - | - | - | 1,500 | - | - | - | 3,400 | - | - | - | 4,200 | - | - | - | 2,500 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -295.0% | -62.60 | 32.00 | 60.00 | -114 | -184 | 93.00 | -74.00 | -15.60 | -37.30 | 328 | 17.00 | -29.70 | 5.00 | 246 | 105 | 128 | 58.00 | 122 | -3.10 | -35.80 | 105 |
Share Based Compensation | 47.5% | 6.00 | 4.00 | 4.00 | 8.00 | 7.00 | 12.00 | 11.00 | 12.00 | 10.00 | 10.00 | 10.00 | 11.00 | 11.00 | 11.00 | 10.00 | 24.00 | 7.00 | 6.00 | 6.00 | 8.00 | 7.00 |
Cashflow From Investing | 5.3% | -10.80 | -11.40 | -18.90 | 258 | -15.10 | -45.40 | -271 | -32.10 | -32.20 | -45.80 | -55.20 | -67.00 | -56.10 | -36.90 | -45.70 | -45.10 | -24.20 | -36.10 | -15.30 | -24.10 | -21.40 |
Cashflow From Financing | 766.0% | 41.00 | 5.00 | -43.00 | -486 | -10.50 | 353 | 229 | -30.70 | -70.50 | -110 | -5.00 | -3.80 | -22.20 | -2.30 | 87.00 | 5.00 | -20.00 | -57.90 | -19.70 | 100 | -58.40 |
Buy Backs | - | - | - | - | - | - | - | - | 23.00 | 52.00 | 106 | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues [Abstract] | ||
Total revenues | $ 300.4 | $ 164.3 |
Operating expenses: | ||
Cost of goods and services sold | 144.6 | 152.9 |
Research and development | 15.1 | 40.7 |
Selling, general and administrative | 84.7 | 101.3 |
Amortization of intangible assets | 16.2 | 17.0 |
Total operating expenses | 260.6 | 311.9 |
Income (loss) from operations | 39.8 | (147.6) |
Other income (expense): | ||
Interest expense | (24.3) | (17.9) |
Other, net | (3.4) | 4.9 |
Total other income (expense), net | (27.7) | (13.0) |
Income (loss) before income taxes | 12.1 | (160.6) |
Income tax provision | 3.1 | 25.6 |
Net income (loss) | $ 9.0 | $ (186.2) |
Earnings Per Share, Diluted [Abstract] | ||
Basic (in dollars per share) | $ 0.17 | $ (3.71) |
Diluted (in dollars per share) | $ 0.17 | $ (3.71) |
Weighted average shares outstanding | ||
Basic (in shares) | 52.2 | 50.2 |
Diluted (in shares) | 52.2 | 50.2 |
Total Product sales, net | ||
Revenues [Abstract] | ||
Product sales | $ 273.9 | $ 143.4 |
Commercial Product sales | ||
Revenues [Abstract] | ||
Product sales | 118.5 | 106.2 |
Operating expenses: | ||
Cost of goods and services sold | 52.1 | 45.8 |
MCM Product sales | ||
Revenues [Abstract] | ||
Product sales | 155.4 | 37.2 |
Operating expenses: | ||
Cost of goods and services sold | 62.2 | 55.4 |
Total Bioservices revenues | ||
Revenues [Abstract] | ||
Total Bioservices revenues | 18.5 | 14.4 |
Operating expenses: | ||
Cost of goods and services sold | 30.3 | 51.7 |
Services | ||
Revenues [Abstract] | ||
Product sales | 18.3 | 12.6 |
Leases | ||
Revenues [Abstract] | ||
Leases | 0.2 | 1.8 |
Contracts and grants | ||
Revenues [Abstract] | ||
Product sales | $ 8.0 | $ 6.5 |
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 78.5 | $ 111.7 |
Restricted cash | 0.5 | 0.0 |
Accounts receivable, net | 233.5 | 191.0 |
Inventories, net | 333.4 | 328.9 |
Prepaid expenses and other current assets | 36.5 | 47.9 |
Total current assets | 682.4 | 679.5 |
Property, plant and equipment, net | 379.4 | 382.8 |
Intangible assets, net | 550.4 | 566.6 |
Other assets | 191.4 | 194.3 |
Total assets | 1,803.6 | 1,823.2 |
Current liabilities: | ||
Accounts payable | 100.2 | 112.2 |
Accrued expenses | 14.3 | 18.6 |
Accrued compensation | 42.0 | 74.1 |
Debt, current portion | 459.2 | 413.7 |
Other current liabilities | 14.5 | 32.7 |
Total current liabilities | 630.2 | 651.3 |
Debt, net of current portion | 446.7 | 446.5 |
Deferred tax liability | 34.8 | 47.2 |
Other liabilities | 28.0 | 28.9 |
Total liabilities | 1,139.7 | 1,173.9 |
Stockholders' equity: | ||
Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding | 0.0 | 0.0 |
Common stock, $0.001 par value per share; 200.0 shares authorized, 58.0 and 57.8 shares issued; 52.4 and 52.2 shares outstanding, respectively | 0.1 | 0.1 |
Treasury stock, at cost, 5.6 and 5.6 common shares, respectively | (227.7) | (227.7) |
Additional paid-in capital | 909.8 | 904.4 |
Accumulated other comprehensive loss, net | (5.5) | (5.7) |
Accumulated deficit | (12.8) | (21.8) |
Total stockholders’ equity | 663.9 | 649.3 |
Total liabilities and stockholders’ equity | $ 1,803.6 | $ 1,823.2 |
 | emergentbiosolutions.com |
---|---|
 | Pharmaceuticals |
 | 2500 |